Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Marker Therapeutics stock

Own Marker Therapeutics stock in just a few minutes.

Marker Therapeutics, Inc is a biotechnology business based in the US. Marker Therapeutics shares (MRKR) are listed on the NASDAQ and all prices are listed in US Dollars. Marker Therapeutics employs 44 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Marker Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MRKR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Marker Therapeutics share price

Use our graph to track the performance of MRKR stocks over time.

Marker Therapeutics shares at a glance

Information last updated 2021-04-21.
52-week range$1.32 - $3.38
50-day moving average $2.23
200-day moving average $1.94
Wall St. target price$6.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-4.17

Buy Marker Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Marker Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Marker Therapeutics financials

Revenue TTM $466,785
Gross profit TTM $-18,413,966
Return on assets TTM -39.26%
Return on equity TTM -80.37%
Profit margin 0%
Book value $0.54
Market capitalisation $156.1 million

TTM: trailing 12 months

Shorting Marker Therapeutics shares

There are currently 3.3 million Marker Therapeutics shares held short by investors – that's known as Marker Therapeutics's "short interest". This figure is 5.7% down from 3.5 million last month.

There are a few different ways that this level of interest in shorting Marker Therapeutics shares can be evaluated.

Marker Therapeutics's "short interest ratio" (SIR)

Marker Therapeutics's "short interest ratio" (SIR) is the quantity of Marker Therapeutics shares currently shorted divided by the average quantity of Marker Therapeutics shares traded daily (recently around 7.7 million). Marker Therapeutics's SIR currently stands at 0.43. In other words for every 100,000 Marker Therapeutics shares traded daily on the market, roughly 430 shares are currently held short.

However Marker Therapeutics's short interest can also be evaluated against the total number of Marker Therapeutics shares, or, against the total number of tradable Marker Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Marker Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Marker Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0517% of the tradable shares (for every 100,000 tradable Marker Therapeutics shares, roughly 52 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Marker Therapeutics.

Find out more about how you can short Marker Therapeutics stock.

Marker Therapeutics share dividends

We're not expecting Marker Therapeutics to pay a dividend over the next 12 months.

Have Marker Therapeutics's shares ever split?

Marker Therapeutics's shares were split on a 1:12 basis on 15 September 2016. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Marker Therapeutics shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Marker Therapeutics shares which in turn could have impacted Marker Therapeutics's share price.

Marker Therapeutics share price volatility

Over the last 12 months, Marker Therapeutics's shares have ranged in value from as little as $1.32 up to $3.38. A popular way to gauge a stock's volatility is its "beta".

MRKR.US volatility(beta: 1.24)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Marker Therapeutics's is 1.2372. This would suggest that Marker Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Marker Therapeutics overview

Marker Therapeutics, Inc. , a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid tumors; and allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. It is also developing TPIV100/110, which is in Phase II clinical trial for the treatment of breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site